综述 |
|
|
|
|
mRNA疫苗的开发及临床研究进展 |
胡瞬1,2,3,4,易有金1,*(),胡涛3,李福胜2,* |
1 湖南农业大学食品科学技术学院 长沙 410128 2 康众(北京)生物科技有限公司 北京 100176 |
|
Development and Clinical Progress of mRNA Vaccine |
HU Shun1,2,3,4,YI You-jin1,*(),HU Tao3,LI Fu-sheng2,* |
1 College of Food Science and Technology, Hunan Agricultural University, Changsha 410128, China 2 Kangzhong (Beijing) Biotechnology Co., Ltd., Beijing 100176, China; Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China; School of Public Healthy, Xiangnan University, Chenzhou 423000, China |
引用本文:
胡瞬,易有金,胡涛,李福胜. mRNA疫苗的开发及临床研究进展[J]. 中国生物工程杂志, 2019, 39(11): 105-112.
HU Shun,YI You-jin,HU Tao,LI Fu-sheng. Development and Clinical Progress of mRNA Vaccine. China Biotechnology, 2019, 39(11): 105-112.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20191112
或
https://manu60.magtech.com.cn/biotech/CN/Y2019/V39/I11/105
|
[1] |
Wolff J A, Malone R W, Williams P , et al. Direct gene transfer into mouse muscle in vivo. Science, 1990,247(4949):1465-1468.
doi: 10.1038/s41434-019-0106-3
pmid: 31624368
|
[2] |
Sahin U, Derhovanessian E, Miller M , et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 2017,547(7662):222-226.
doi: 10.1038/nature23003
pmid: 28678784
|
[3] |
Kormann M S D, Hasenpusch G, Aneja M K , et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nature Biotechnology, 2011,29(2):154-157.
doi: 10.1038/nbt.1733
pmid: 21217696
|
[4] |
Peng Z H, Sharma V, Singleton S F , et al. Synjournal and application of a chain-terminating dinucleotide mRNA cap analog. Organic Letters, 2002,4(2):161-164.
doi: 10.1021/ol0167715
pmid: 11796040
|
[5] |
Stepinski J, Waddell C, Stolarski R , et al. Synjournal and properties of mRNAs containing the novel “anti-reverse” cap analogues 7-methyl(3-O-methyl)GpppG and 7-methyl(3-deoxy)GpppG. RNA, 2001,7(10):1486-1495.
pmid: 11680853
|
[6] |
Jemielity J, Fowler T, Zuberek J , et al. Novel “Anti-Reverse” cap analogues with superior translational properties. RNA, 2003,9(9):1108-1122.
doi: 10.1261/rna.5430403
pmid: 12923259
|
[7] |
Grudzien-Nogalska E, Stepinski J, Jemielity J , et al. Synjournal of anti-reverse cap analogs (ARCAs)and their applications in mRNA translation and stability. Methods in Enzymology, 2007,431:203-227.
doi: 10.1016/S0076-6879(07)31011-2
pmid: 17923237
|
[8] |
Kuhn A N, Diken M, Kreiter S , et al. Phosphorothioate cap analogs increase stability and translational effciency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Therapy, 2010,17(8):961-971.
doi: 10.1038/gt.2010.52
pmid: 20410931
|
[9] |
Kore A R, Shanmugasundaram M, Charles I , et al. Locked nucleic acid (LNA)-modified dinucleotide mRNA cap analogue: synjournal, enzymatic incorporation, and utilization. Journal of the American Chemical Society, 2009,131(18):6364-6365.
doi: 10.1021/ja901655p
pmid: 19385620
|
[10] |
Grudzien E, Stepinski J, Jankowska-Anyszka M , et al. Novel cap analogs for in vitro synjournal of mRNAs with high translational efficiency. RNA, 2004,10(9):1479-1487.
doi: 10.1261/rna.7380904
pmid: 15317978
|
[11] |
Gray N K, Wickens M . Control of translation initiation in animals. Annual Review of Cell and Developmental Biology, 1998,14(1):399-458.
doi: 10.16288/j.yczz.19-045
pmid: 31624057
|
[12] |
Kozak M . At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. Journal of Molecular Biology, 1987,196(4):947-950.
doi: 10.1016/0022-2836(87)90418-9
pmid: 3681984
|
[13] |
Pelletier J, Sonenberg N . Insertion mutagenesis to increase secondary structure within the 5' noncoding region of a eukaryotic mRNA reduces translational efficiency. Cell, 1985,40(3):515-526.
doi: 10.1016/0092-8674(85)90200-4
pmid: 2982496
|
[14] |
Chen C Y, Shyu A B . AU-rich elements: characterization and importance in mRNA degradation. Trends in Biochemical Sciences, 1995,20(11):465-470.
doi: 10.1016/s0968-0004(00)89102-1
pmid: 8578590
|
[15] |
Murray E L, Schoenberg D R . A + U-rich instability elements differentially activate 5'-3' and 3'-5' mRNA decay. Molecular and Cellular Biology, 2007,27(8):2791-2799.
doi: 10.1128/MCB.01445-06
pmid: 17296726
|
[16] |
Vlasova-St L I, Bohjanen P R . Coordinate regulation of mRNA decay networks by GU-rich elements and CELF1. Current Opinion in Genetics & Development, 2011,21(4):444-451.
doi: 10.1016/j.pathol.2019.09.008
pmid: 31735344
|
[17] |
Sahin U, Holtkamp S, Türecl ? , et al. Modification of RNA, producing an increased transcript stability and translation efficiency: US, US2019/0062762 A1. 2019-2-28[2019-03-01]. .
|
[18] |
Ferizi M, Leonhardt C, Meggle C , et al. Stability analysis of chemically modified mRNA using micropattern-based single-cell arrays. Lab on a Chip, 2015,15(17):3561-3571.
doi: 10.1039/c5lc00749f
pmid: 26201602
|
[19] |
Wang Z, Kiledjian M . The poly(A)-binding protein and an mRNA stability protein jointly regulate an endoribonuclease activity. Molecular and Cellular Biology, 2000,20(17):6334-6341.
doi: 10.1128/mcb.20.17.6334-6341.2000
pmid: 10938110
|
[20] |
Van der Velden A W, Voorma H O , Thomas A A. Vector design for optimal protein expression. Biotechniques, 2001, 31(3):572, 574, 576-580.
doi: 10.1007/s12033-019-00218-x
pmid: 31664704
|
[21] |
Alexopoulou L, Holt A C, Medzhitov R , et al. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature, 2001,413(6857):732-738.
doi: 10.1038/35099560
pmid: 11607032
|
[22] |
Diebold S S, Kaisho T, Hemmi H , et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science, 2004,303(5663):1529-1531.
doi: 10.1126/science.1093616
pmid: 14976261
|
[23] |
Heil F, Hemmi H, Hochrein H , et al. Species-specifc recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science, 2004,303(5663):1526-1529.
doi: 10.1126/science.1093620
pmid: 14976262
|
[24] |
Karikó K, Buckstein M, Ni H , et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 2005,23(2):165-175.
doi: 10.1016/j.immuni.2005.06.008
pmid: 16111635
|
[25] |
Pardi N, Parkhouse K, Kirkpatrick E , et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nature Communications, 2018,9(1):3361.
doi: 10.1038/s41467-018-05482-0
pmid: 30135514
|
[26] |
Pardi ,N, Parkhouse K,Kirkpatrick E, , et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature, 2017,543(7644):248-251.
doi: 10.1038/nature21428
pmid: 28151488
|
[27] |
Thess A, Grund S, Mui B L , et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Molecular Therapy, 2015,23(9):1456-1464.
doi: 10.1038/mt.2015.103
pmid: 26050989
|
[28] |
Karikó K, Muramatsu H, Welsh F A , et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Molecular Therapy, 2008,16(11):1833-1840.
doi: 10.1038/mt.2008.200
pmid: 18797453
|
[29] |
Kormann M S, Hasenpusch G, Aneja M K , et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nature Biotechnology, 2011,29(2):154-157.
doi: 10.1038/nbt.1733
pmid: 21217696
|
[30] |
Mays L E, Ammon Treiber S, Mothes B , et al. Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism. Journal of Clinical Investigation, 2013,123(3):1216-1228.
doi: 10.1172/JCI65351
|
[31] |
Sahin U, Karikó K , Türeci ?. mRNA-based therapeutics-developing a new class of drugs. Nature Reviews Drug Discovery, 2014,13(10):759-780.
doi: 10.1038/nrd4278
|
[32] |
Heiser A, Coleman D, Dannull J , et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. Journal of Clinical Investigation, 2002,109(3):409-417.
doi: 10.1172/JCI14364
pmid: 11828001
|
[33] |
Rejman J, Oberle V, Zuhorn I S , et al. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochemical Journal, 2004,377(1):159-169.
doi: 10.1016/j.imbio.2014.06.002
pmid: 25082708
|
[34] |
Ma Z, Li J, He F , et al. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochemical and Biophysical Research Communications, 2005,330(3):755-759.
doi: 10.1016/j.bbrc.2005.03.041
pmid: 15809061
|
[35] |
Landesman-Milo D, Peer D . Toxicity profiling of several common RNAi-based nanomedicines: a comparative study. Drug Delivery and Translational Research, 2014,4(1):96-103.
doi: 10.1007/s13346-013-0158-7
pmid: 25786620
|
[36] |
Islam M A ,Reesor E K G,Xu Y, et al. Biomaterials for mRNA delivery. Biomaterials Science, 2015,3(12):1519-1533.
doi: 10.1039/c5bm00198f
pmid: 26280625
|
[37] |
Maier M A, Jayaraman M, Matsuda S , et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Molecular Therapy, 2013,21(8):1570-1578.
doi: 10.1038/mt.2013.124
|
[38] |
Jayaraman M, Ansell S M, Mui B L , et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angewandte Chemie International Edition. 2012,124(34):8529-8533.
doi: 10.1002/anie.201203263
pmid: 22782619
|
[39] |
Pardi N, Tuyishime S, Muramatsu H , et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. Journal of Controlled Release, 2015,217:345-351.
doi: 10.1016/j.jconrel.2015.08.007
pmid: 26264835
|
[40] |
Sedic M, Senn J J, Lynn A , et al. Safety evaluation of lipid nanoparticle-formulated modified mRNA in the Sprague-Dawley rat and cynomolgus monkey. Veterinary Pathology, 2017,55(2):341-354.
doi: 10.1177/0300985817738095
pmid: 29191134
|
[41] |
Rizk M, Tüzmen S X . Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran. Pharmacogenomics and Personalized Medicine, 2017,2017(10):267-278.
doi: 10.2147/PGPM.S87945
pmid: 29184431
|
[42] |
Zhao M, Li M, Zhang Z , et al. Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA. Drug Delivery, 2016,23(7):2596-2607.
doi: 10.3109/10717544.2015.1038856
pmid: 26024387
|
[43] |
Li M, Zhao M, Fu Y , et al. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier viaintra- and paracellular pathways. Journal of Controlled Release, 2016,228:9-19.
doi: 10.1016/j.jconrel.2016.02.043
pmid: 26941035
|
[44] |
Dong Y, Dorkin J R, Wang W , et al. Poly ( glycoamidoamine ) brushes formulated nanomaterials for systemic siRNA and mRNA delivery in vivo. Nano Letters, 2016,16(2):842-848.
doi: 10.1021/acs.nanolett.5b02428
pmid: 26727632
|
[45] |
Prieve M G, Harvie P, Monahan S D , et al. Targeted mRNA therapy for ornithine transcarbamylase deficiency. Molecular Therapy, 2018,26(3):801-813.
doi: 10.1016/j.ymthe.2017.12.024
pmid: 29433939
|
[46] |
Gandhi R T, Kwon D S, Macklin E A , et al. Immunization of HIV-1-infected persons with autologous dendritic cells transfected with mRNA encoding HIV-1 gag and Nef. Journal of Acquired Immune Deficiency Syndromes, 2016,71(3):246-253.
doi: 10.1097/QAI.0000000000000852
pmid: 26379068
|
[47] |
Kyte J A, Kvalheim G, Lislerud K , et al. T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunology, Immunotherapy, 2006,56(5):659-675.
doi: 10.1007/s00262-006-0222-y
pmid: 16947019
|
[48] |
Kyte J A, Mu L, Aamdal S , et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Therapy, 2006,13(10):905-918.
doi: 10.1038/sj.cgt.7700961
pmid: 16710345
|
[49] |
Weide B ,Pascolo, S, Scheel B, et al. Direct Injection of protamine-protected mRNA: Results of a phase 1/2 vaccination trial in metastatic melanoma patients. Journal of Immunotherapy, 2009,32(5):498-507.
doi: 10.1097/CJI.0b013e3181a00068
pmid: 19609242
|
[50] |
Wilgenhof S, Van Nuffel A M T, Benteyn D,et al. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Annals of Oncology, 2013,24(10):2686-2693.
doi: 10.1093/annonc/mdt245
|
[51] |
Gan L M, Lagerstr?m Fermér M, Carlsson L G , et al. Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes. Nature Communications, 2019,10(1):871.
doi: 10.1038/s41467-019-08852-4
pmid: 30787295
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|